medigraphic.com
Instituto Nacional de Salud Pública

2023, Number 6

<< Back

salud publica mex 2023; 65 (6)

Screening, prevalence, awareness, treatment, and control of hypertension, dyslipidemia and diabetes in Mexican adults. Ensanut 2022

Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A, Barrientos-Gutiérrez T, Romero-Martínez M, Aguilar-Salinas C

Language: Spanish
References: 34
Page: 685-696
PDF size: 312.63 Kb.


ABSTRACT

Objective. To describe the estimates of screening, prevalence, previous diagnosis, treatment and control of hypertension, hypercholesterolemia and diabetes, as well as their associated factors in Mexican adults. Materials and methods. Information from adults aged 20 years and over participating in the Encuesta Nacional de Salud y Nutrición 2022 (Ensanut 2022) was used. Prevalence estimates are presented with their 95% confidence intervals, and multiple logistic regression models for each condition, with factors associated with screening, awareness, treatment, and control. Results. Screening for these three diseases is low, less than 15%. The prevalence of hypercholesterolemia and diabetes is 18% and prevalence of hypertension is 27.6%; about half know their diagnosis. The proportion of patients with pharmacological treatment has increased, but less than a half of them are in control. Conclusion. It is recommended that the detection of these diseases be done in an integrated way with other cardiovascular risk factors. It is necessary to increase the percentages of screening, increase the awareness, improve the percentage of medical treatment for these diseases, and above all increase the proportion of patients in treatment with metabolic control.


REFERENCES

  1. Mensah GA, Roth GA, Fuster V. The global burden of cardiovasculardiseases and risk factors: 2020 and beyond. J AM Coll Cardiol. 2019;74(20):2529-32. https://doi.org/10.1016/j.jacc.2019.10.009

  2. Instituto Nacional de Estadística y Geografía. Estadística de defuncionesregistradas de enero a junio de 2022. México: Inegi, 2023 [citado mayo 22,2023]. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2023/DR/DR-Ene-jun2022.pdf

  3. Kivimäki M, Shipley MJ, Ferrie JE, Singh-Manoux A, Batty GD, ChandolaT, et al. Best-practice interventions to reduce socioeconomic inequalitiesof coronary heart disease mortality in UK: a prospective occupational cohortstudy. The Lancet. 2008;372(9650):1648-54. https://doi.org/10.1016/S0140-6736(08)61688-8

  4. Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M,Haines A. Improving the prevention and management of chronic diseasein low-income and middle-income countries: a priority for primary healthcare. The Lancet. 2008;372(9642):940-49. https://doi.org/10.1016/S0140-6736(08)61404-X

  5. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, et al. Encuesta Nacional deSalud y Nutrición 2021 sobre Covid-19. Resultados nacionales. Cuernavaca:INSP, 2022 [citado mayo 4, 2023]. Disponible en: https://ensanut.insp.mx/encuestas/ensanutcontinua2021/informes.php

  6. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, Borch-Johnsen, K. Screen-detected diabetes, hypertension and hypercholesterolemiaas predictors of cardiovascular mortality in five populations ofAsian origin: the DECODA study. EJPC. 2006;13(4):555-61. https://doi.org/10.1097/01.hjr.0000183916.28354.69

  7. Escamilla-Núñez MC, Castro-Porras L, Romero-Martínez M, Zárate-Rojas E, Rojas-Martínez R. Detección, diagnóstico previo y tratamientode enfermedades crónicas no transmisibles en adultos mexicanos.Ensanut 2022. Salud Publica Mex. 2023;65(supl 1):S153-62. https://doi.org/10.21149/14726

  8. Institute for Health Metrics and Evaluation. Global Burden of Disease2019. Seattle: IHME, 2023 [citado abril 18, 2023]. Disponible en: https://vizhub.healthdata.org/gbd-compare/

  9. Kivimäki M, Shipley MJ, Ferrie JE, Singh-Manoux A, Batty GD, ChandolaT, et al. Best-practice interventions to reduce socioeconomic inequalitiesof coronary heart disease mortality in UK: a prospective occupational cohortstudy. The Lancet. 2008;372(9650):1648-54. https://doi.org/10.1016/S0140-6736(08)61688-8

  10. Giordano TP. The HIV treatment cascade—a new tool in HIV prevention.JAMA Intern Med. 2015;175(4):596-7. https://doi.org/10.1001/jamainternmed.2014.8199

  11. Kazemian P, Shebl FM, McCann N, Walensky RP, Wexler DJ. Evaluationof the cascade of diabetes care in the United States, 2005-2016. JAMAIntern Med. 2019;179(10):1376-85. https://doi.org/10.1001/jamainternmed.2019.2396

  12. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K,Pedroza-Tobías A, Villalpando, S, Shamah-Levy T, et al. Dyslipidemiaprevalence, awareness, treatment and control in Mexico: results ofthe Ensanut 2012. Salud Publica Mex. 2020;62(2):137-46. https://doi.org/10.21149/10520

  13. Campos-Nonato I, Hernandez-Barrera L, Pedroza-Tobias A, MedinaC, Barquera S. Hypertension in Mexican adults: prevalence, diagnosis andtype of treatment. Ensanut MC 2016. Salud Publica Mex. 2018;60(3):233-43. https://doi.org/10.21149/8813

  14. Barquera S, Hernández-Alcaraz C, Jáuregui A, Medina C, Mendoza-Herrera K, Pedroza-Tobias A, et al. Diabetes awareness, treatment, andcontrol among Mexico City residents. Diabetology. 2021;2(1):16-30.https://doi.org/10.3390/diabetology2010002

  15. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, Gaona-Pineda EB, et al. Metodología de laEncuesta Nacional de Salud y Nutrición 2022 y Planeación y diseño de laEnsanut Continua 2020-2024. Salud Publica Mex. 2022;64(5):522-9. https://doi.org/10.21149/14186

  16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, IzzoJrJL, et al. National High Blood Pressure Education Program CoordinatingCommittee. Seventh report of the joint national committee onprevention, detection, evaluation, and treatment of high blood pressure.Hypertension. 2003;42(6):1206-52. https://doi.org/10.1161/01.HYP.0000107251.49515.c2

  17. Expert Panel on Detection, Evaluation, and Treatment of High BloodCholesterol in Adults. Executive Summary of The Third Report of TheNational Cholesterol Education Program (NCEP). JAMA. 2001;285:2486--97. https://doi.org/10.1001/jama.285.19.2486

  18. American Diabetes Association. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Supp 1):S15-33. https://doi.org/10.2337/dc21-S002

  19. Assessment G, American Diabetes Association. 6. glycemic targets:Standards of medical care in diabetes 2021. Diabetes Care. 2021;44(Supp1):S73-584. https://doi.org/10.2337/dc21-S006

  20. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T,Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, et al. EncuestaNacional de Salud y Nutrición 2021 sobr e Covid-19. Resultados nacionales.Cuernavaca: Instituto Nacional de Salud Pública, 2022 [citadomayo 22, 2023]. Disponible en: https://ensanut.insp.mx/encuestas/ensanutcontinua2021/informes.php

  21. Selby K, Banatvala N, Bovet P, Cornuz J. Screening and health checksfor NCD prevention and control. Global Action Plan for the Preventionand Control of NCDs 2013-2030. En: Banatvala N, Bovet P. NoncommunicableDiseases. A Compendium. Londres: Routledge, 2023 [citadomayo 12, 2023]. Disponible en: https://www.taylorfrancis.com/books/oaedit/10.4324/9781003306689/noncommunicable-diseases-nick-banatvalapascal-bovet

  22. Chou, R. Routine screening for chronic human immunodeficiencyvirus infection: why don’t the guidelines agree?. Epidemiologic Reviews.2011;33(1):7-19. https://doi.org/10.1093/epirev/mxr001

  23. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-030-SSA2-2009, Para la prevención, detección, diagnóstico, tratamiento ycontrol de la hipertensión arterial sistémica. México: 2010 [citado mayo 3,2023]. Disponible en: https://www.cndh.org.mx/DocTR/2016/JUR/A70/01/JUR-20170331-NOR21.pdf

  24. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemiasMéxico: 2012 [citado mayo 3, 2023]. Disponible en: https://www.cndh.org.mx/DocTR/2016/JUR/A70/01/JUR-20170331-NOR36.pdf

  25. Diario Oficial de la Federación, 23 de noviembre de 2010. Norma OficialMexicana NOM-015-SSA2-2010, Para la prevención, tratamiento y control dela diabetes mellitus. México: DOF, 2010 [citado noviembre 23, 2023]. Disponibleen: http://www.dof.gob.mx/normasOficiales/4215/salud/salud.htm

  26. Centro Nacional de Programas Preventivos y Control de Enfermedades.Programa de Acción Específico Enfermedades Cardiometabólicas2020-2024. México: Secretaría de Salud, 2021 [citado mayo 4, 2023].Disponible en: https://www.gob.mx/cms/uploads/attachment/file/714141/PAE_CME_cF.pdf

  27. Secretaría de Salud. Cuestionario de Factores de Riesgo. México: Secretaríade Salud, 2015 [citado mayo 4, 2023]. Disponible en: https://www.gob.mx/salud/en/documentos/cuestionario-de-factores-de-riesgo

  28. Barquera S, Campos-Nonato I, Hernández-Barrera L, Villalpando S,Rodríguez-Gilabert C, Durazo-Arvizú R, Aguilar-Salinas CA. Hypertensionin Mexican adults: results from the National Health and Nutrition Survey2006. Salud Publica Mexico. 2010;52(supl 1):S63-71.

  29. Campos-Nonato I, Hernández-Barrera L, Rojas-Martínez R, Pedroza A,Medina-García C, Barquera-Cervera S. Hipertensión arterial: prevalencia,diagnóstico oportuno, control y tendencias en adultos mexicanos. SaludPublica Mex. 2013;55(supl 2):S144-50.

  30. Campos-Nonato I, Hernández-Barrera L, Pedroza-Tobías A, MedinaC, Barquera S. Hipertensión arterial en adultos mexicanos: prevalencia,diagnóstico y tipo de tratamiento. Ensanut MC 2016. Salud Publica Mex.2018;60(3):233-43. https://doi.org/10.21149/8813

  31. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K,Pedroza-Tobías A, Villalpando S, Shamah-Levy T, Rivera-Dommarco J, etal. Dyslipidemia prevalence, awareness, treatment and control in Mexico:results of the Ensanut 2012. Salud Publica Mex. 2020;62:137-46. https://doi.org/10.21149/10520

  32. Guadamuz JS, Durazo-Arvizu RA, Daviglus ML, Calip GS, Nutescu EA,Qato DM. Citizenship status and the prevalence, treatment, and controlof cardiovascular disease risk factors among adults in the United States,2011-2016. Circ Cardiovasc Qual Outcomes. 2020;13(3):e006215. https://doi.org/10.1161/CIRCOUTCOMES.119.006215

  33. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-SalinasCA, De la Cruz-Góngora, V, Rivera-Dommarco J, et al. Prevalence of diabetesand glycemic control in Mexico: national results from 2018 and 2020.Salud Publica Mex. 2021;63(6):725-33. https://doi.org/10.21149/12842

  34. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med.2013;369(14):1336-43. https://doi.org/10.1056/NEJMra1109345




2020     |     www.medigraphic.com